← Back to Search

Other

Oral CT1812 for Age-Related Macular Degeneration

Phase 2
Recruiting
Research Sponsored by Cognition Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through week 104
Awards & highlights

Study Summary

This trial will test a new drug to treat dry age-related macular degeneration, assessing safety, effectiveness, and how well people tolerate it.

Who is the study for?
This trial is for people over 50 with a specific eye condition called Geographic Atrophy due to dry Age-Related Macular Degeneration. Participants must have decent vision and stable health conditions. Those with recent eye surgeries, other serious eye diseases, or allergies to study drugs can't join.Check my eligibility
What is being tested?
The study tests the effectiveness of an oral drug named CT1812 against a placebo in improving this eye condition. It's a double-masked trial, meaning neither participants nor researchers know who gets the real drug or placebo during the 104-week study.See study design
What are the potential side effects?
While not specified here, side effects may include typical reactions to oral medications such as stomach upset, headache, dizziness, or allergic reactions. The safety profile will be closely monitored throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through week 104
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through week 104 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye.
Secondary outcome measures
Plasma concentration of CT1812
Safety and Tolerability of CT1812

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: CT1812 200 mgActive Control1 Intervention
Drug: CT1812 Active Study Drug
Group II: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Cognition TherapeuticsLead Sponsor
11 Previous Clinical Trials
1,258 Total Patients Enrolled
Anthony CaggianoStudy DirectorCognition Therapeutics Inc.

Media Library

CT1812 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05893537 — Phase 2
Age-Related Macular Degeneration Research Study Groups: Placebo, CT1812 200 mg
Age-Related Macular Degeneration Clinical Trial 2023: CT1812 Highlights & Side Effects. Trial Name: NCT05893537 — Phase 2
CT1812 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05893537 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this clinical trial currently accessible to the public?

"Confirmed. Clinicaltrials.gov reports that this medical study is still actively seeking out participants, with the trial first posted on June 16th 2023 and recently updated at the end of that same month."

Answered by AI

How many people are currently enrolled in this clinical trial?

"Correct. According to information posted on clinicaltrials.gov, this research is actively seeking participants, having been first cataloged on June 16th 2023 and most recently updated June 30th of the same year. This investigation requires 246 individuals to be enrolled from 4 distinct sites."

Answered by AI

Are there numerous locations executing this clinical investigation in the locality?

"This experimental trial is currently administered through 4 distinct medical sites, namely those located in Erie, Burleson and Fort Worth as well as a supplementary four. To minimize the amount of travel required if you decide to take part, it's highly recommended that you select the institution closest to your residence."

Answered by AI

Has the FDA approved CT1812 200 mg for distribution?

"The safety of the CT1812 200 mg drug was rated a 2 on our rating scale, as Phase 2 trials have provided some evidence for its safety but not yet any data in support of efficacy."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What site did they apply to?
Texas Retina Associates
Retinal Consultants Medical Group
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
2023. "Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05893537.
All > Age Related Macular Degeneration > Geographic Atrophy
~164 spots leftby Jul 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top